KR101468737B1 - 에리트로포이에틴 변이체 - Google Patents

에리트로포이에틴 변이체 Download PDF

Info

Publication number
KR101468737B1
KR101468737B1 KR1020077026286A KR20077026286A KR101468737B1 KR 101468737 B1 KR101468737 B1 KR 101468737B1 KR 1020077026286 A KR1020077026286 A KR 1020077026286A KR 20077026286 A KR20077026286 A KR 20077026286A KR 101468737 B1 KR101468737 B1 KR 101468737B1
Authority
KR
South Korea
Prior art keywords
leu
polynucleotide
epo
polypeptide
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020077026286A
Other languages
English (en)
Korean (ko)
Other versions
KR20080021595A (ko
Inventor
안드레아스 마이젤
조세프 프릴레르
크리스텔 본나스
울리히 디르나글
Original Assignee
카리테 유니페르지테츠메디친 - 베를린
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 카리테 유니페르지테츠메디친 - 베를린 filed Critical 카리테 유니페르지테츠메디친 - 베를린
Publication of KR20080021595A publication Critical patent/KR20080021595A/ko
Application granted granted Critical
Publication of KR101468737B1 publication Critical patent/KR101468737B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020077026286A 2005-05-13 2006-05-15 에리트로포이에틴 변이체 Expired - Fee Related KR101468737B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05010473.6 2005-05-13
EP05010473A EP1736481A1 (en) 2005-05-13 2005-05-13 Erythropoietin variants
PCT/EP2006/004564 WO2006120030A1 (en) 2005-05-13 2006-05-15 Erythropoietin variants

Publications (2)

Publication Number Publication Date
KR20080021595A KR20080021595A (ko) 2008-03-07
KR101468737B1 true KR101468737B1 (ko) 2014-12-09

Family

ID=36753959

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020077026286A Expired - Fee Related KR101468737B1 (ko) 2005-05-13 2006-05-15 에리트로포이에틴 변이체

Country Status (12)

Country Link
EP (2) EP1736481A1 (enExample)
JP (1) JP5231214B2 (enExample)
KR (1) KR101468737B1 (enExample)
CN (1) CN101175768B (enExample)
AU (1) AU2006245916B2 (enExample)
BR (1) BRPI0608769A2 (enExample)
CA (1) CA2608379C (enExample)
DK (1) DK1885747T3 (enExample)
ES (1) ES2457398T3 (enExample)
RU (1) RU2430162C2 (enExample)
WO (1) WO2006120030A1 (enExample)
ZA (1) ZA200709091B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190038528A (ko) * 2017-02-27 2019-04-08 재단법인대구경북과학기술원 에리스로포이에틴 유래 펩티드의 세포손상방지에 효과를 통한 활용

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1924276A4 (en) 2005-08-05 2009-07-22 Araim Pharmaceuticals Inc Antiperspirant peptides and their uses
US20100267576A1 (en) * 2007-05-02 2010-10-21 University Of Utah Research Foundation Compositions And Methods For Identifying And Treating Subjects At Risk Of Developing Type 2 Diabetes
DE102007031708A1 (de) 2007-07-06 2009-01-08 Dade Behring Marburg Gmbh Bestimmung der von Willebrand Faktor-Aktivität in Abwesenheit von Ristocetin
WO2009094172A2 (en) 2008-01-22 2009-07-30 Araim Pharmaceuticals, Inc. Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
AU2011377617B2 (en) 2011-09-23 2018-03-08 Bluebird Bio, Inc. Improved gene therapy methods
KR101148191B1 (ko) * 2011-09-27 2012-05-23 김후정 에리스로포이에틴-유래 펩타이드 및 그 용도
DK2928921T3 (da) 2012-12-05 2021-04-19 Novartis Ag Sammensætninger og fremgangsmåder til antistoffer målrettet epo
CN105072914B (zh) 2013-02-06 2018-09-21 Nc医学研究公司 用于治疗神经变性的细胞疗法
ES2913530T3 (es) 2015-08-12 2022-06-02 Novartis Ag Métodos para tratar trastornos oftálmicos
HK1257024A1 (zh) 2015-08-31 2019-10-11 宾夕法尼亚大学 用於治疗伴侣动物的aav-epo
CN107880109B (zh) * 2017-11-01 2019-08-30 复旦大学附属中山医院 一种促红细胞生成素来源肽及其制备方法和用途
AR113091A1 (es) * 2018-09-27 2020-01-22 Univ Nacional Del Litoral Eritropoyetina humana modificada
US11566056B2 (en) 2020-05-26 2023-01-31 Sylus Co., Ltd Peptide and use thereof for treatment of disease of brain and nervous system
CN113376186B (zh) * 2021-05-12 2022-12-23 无锡科金生物科技有限公司 一种精准度高的智能红细胞叶酸检测仪及其检测方法
CA3222471A1 (en) * 2021-06-15 2022-12-22 Giovanni MARFIA Epo variants and modulators

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004003176A2 (en) * 2002-07-01 2004-01-08 The Kenneth S. Warren Institute, Inc. Recombinant tissue protective cytokines and encoding nucleic acids thereof for protection, restoration, and enhancement of responsive cells, tissues, and organs
WO2004043382A2 (en) * 2002-11-08 2004-05-27 Egea Biosciences, Inc. Enhanced variants of erythropoietin and methods of use

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4558006A (en) * 1983-02-04 1985-12-10 Kirin-Amgen, Inc. A.T.C.C. HB8209 and its monoclonal antibody to erythropoietin
DE3924746A1 (de) * 1989-07-26 1991-01-31 Behringwerke Ag Erythropoietin (epo)-peptide und dagegen gerichtete antikoerper
IL110669A (en) 1993-08-17 2008-11-26 Kirin Amgen Inc Erythropoietin analogs
US6271196B1 (en) * 1996-03-05 2001-08-07 Regents Of The University Of Ca Methods of alleviating neuropathic pain using prosaposin-derived peptides
DE19857609A1 (de) 1998-12-14 2000-06-15 Hannelore Ehrenreich Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen
US7259146B2 (en) 2000-05-26 2007-08-21 Ortho-Mcneil Pharmaceutical, Inc. Neuroprotective peptides
DE10043457A1 (de) 2000-09-04 2002-03-28 Hannelore Ehrenreich Verfahren zur Behandlung von Schizophrenie und verwandten Psychosen sowie Verwendung von Erythropoietin oder Erythropoietinderivaten zur Behandlung von Schizophrenien und verwandten Psychosen
US6531121B2 (en) 2000-12-29 2003-03-11 The Kenneth S. Warren Institute, Inc. Protection and enhancement of erythropoietin-responsive cells, tissues and organs
WO2005025606A1 (en) 2003-09-09 2005-03-24 Warren Pharmaceuticals, Inc. Long acting erythropoietins that maintain tissue protective activity of endogenous erythropoietin
CA2563874A1 (en) * 2004-04-23 2005-11-03 Cambridge Antibody Technology Limited Erythropoietin protein variants

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004003176A2 (en) * 2002-07-01 2004-01-08 The Kenneth S. Warren Institute, Inc. Recombinant tissue protective cytokines and encoding nucleic acids thereof for protection, restoration, and enhancement of responsive cells, tissues, and organs
WO2004043382A2 (en) * 2002-11-08 2004-05-27 Egea Biosciences, Inc. Enhanced variants of erythropoietin and methods of use

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190038528A (ko) * 2017-02-27 2019-04-08 재단법인대구경북과학기술원 에리스로포이에틴 유래 펩티드의 세포손상방지에 효과를 통한 활용
KR102345605B1 (ko) 2017-02-27 2021-12-31 주식회사 사이루스 에리스로포이에틴 유래 펩티드의 세포손상방지에 효과를 통한 활용

Also Published As

Publication number Publication date
CN101175768B (zh) 2013-09-11
WO2006120030A1 (en) 2006-11-16
KR20080021595A (ko) 2008-03-07
ZA200709091B (en) 2009-08-26
CN101175768A (zh) 2008-05-07
JP2008539745A (ja) 2008-11-20
ES2457398T3 (es) 2014-04-25
EP1885747B1 (en) 2013-11-20
WO2006120030A8 (en) 2006-12-28
EP1736481A1 (en) 2006-12-27
CA2608379C (en) 2014-12-16
RU2430162C2 (ru) 2011-09-27
RU2007146455A (ru) 2009-06-20
CA2608379A1 (en) 2006-11-16
JP5231214B2 (ja) 2013-07-10
AU2006245916A1 (en) 2006-11-16
DK1885747T3 (en) 2014-02-24
BRPI0608769A2 (pt) 2010-01-26
AU2006245916B2 (en) 2012-03-15
EP1885747A1 (en) 2008-02-13

Similar Documents

Publication Publication Date Title
US20190106470A1 (en) Erythropoietin variants
US10046027B2 (en) Muteins of tear lipocalin and methods for obtaining the same
JP4793836B2 (ja) 線維芽細胞増殖因子様ポリペプチド
EP1885747B1 (en) Erythropoietin variants
CA2808392C (en) Binding proteins for hepcidin
JP6527925B2 (ja) インターロイキン４およびインターロイキンを含む融合タンパク質
WO2001007595A2 (en) Novel fibroblast growth factor and nucleic acids encoding same
JP2018535964A (ja) 線維芽細胞増殖因子（ｆｇｆ）１アナログによるステロイド誘導性高血糖の処置
WO2014000042A1 (en) COMPOSITIONS AND METHODS FOR MODIFYING TGF-β FAMILY LIGANDS
JP2009517009A (ja) エリスロポエチンポリペプチド及びそれらの使用
US20040241800A1 (en) Vascular endothelial growth factor dimers
KR20040089093A (ko) 시스틴-결절 폴드 단백질
CA2352495A1 (en) Human semaphorin 6a-1 (sema6a-a), a gene involved in neuronal development and regeneration mechanisms during apoptosis, and its use as a potential drug target
JP2002538823A (ja) 脊椎動物のｓｌｉｔＤＮＡ配列、タンパク質およびその使用
WO2009116529A1 (ja) ポリペプチドおよび当該ポリペプチドを含む医薬組成物
CA2464344A1 (en) Ee3-protein family and corresponding dna sequences

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

St.27 status event code: A-3-3-V10-V11-apl-PJ0201

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PB0901 Examination by re-examination before a trial

St.27 status event code: A-6-3-E10-E12-rex-PB0901

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

St.27 status event code: A-3-4-F10-F13-rex-PB0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20171116

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20191128

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20191128